title: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.
abstract: BACKGROUND
  To make well informed treatment decisions for their patients, clinicians need credible information about potential risk for substantial weight gain. We therefore conducted a post-hoc analysis of clinical trial data, examining early weight gain as a predictor of later substantial weight gain.
  
  
  METHODS
  Data from 669 (Study 1) and 102 (Study 2) olanzapine-treated patients diagnosed with schizophrenia, schizophreniform, or schizoaffective disorder were analyzed to identify and validate weight gain cut-offs at Weeks 1-4 that were predictive of substantial weight gain (defined as an increase of > or = 5, 7, 10 kg or 7% of baseline weight) after approximately 30 weeks of treatment. Baseline characteristics alone, baseline characteristics plus weight change from baseline to Weeks 1, 2, 3 or 4, and weight change from baseline to Weeks 1, 2, 3, or 4 alone were evaluated as predictors of substantial weight gain. Similar analyses were performed to determine BMI increase cut-offs at Weeks 1-4 of treatment that were predictive of substantial increase in BMI (1, 2 or 3 kg/m2 increase from baseline).
  
  
  RESULTS
  At Weeks 1 and 2, predictions based on early weight gain plus baseline characteristics were more robust than those based on early weight gain alone. However, by Weeks 3 and 4, there was little difference between the operating characteristics associated with these two sets of predictors. The positive predictive values ranged from 30.1% to 73.5%, while the negative predictive values ranged from 58.1% to 89.0%. Predictions based on early BMI increase plus baseline characteristics were not uniformly more robust at any time compared to those based on early BMI increase alone. The positive predictive values ranged from 38.3% to 83.5%, while negative predictive values ranged from 42.1% to 84.7%. For analyses of both early weight gain and early BMI increase, results for the validation dataset were similar to those observed in the primary dataset.
  
  
  CONCLUSIONS
  Results from these analyses can be used by clinicians to evaluate risk of substantial weight gain or BMI increase for individual patients. For instance, negative predictive values based on data from these studies suggest approximately 88% of patients who gain less than 2 kg by Week 3 will gain less than 10 kg after 26-34 weeks of olanzapine treatment. Analysis of changes in BMI suggests that approximately 84% of patients who gain less than .64 kg/m2 in BMI by Week 3 will gain less than 3 kg/m2 in BMI after 26-34 weeks of olanzapine treatment. Further research in larger patient populations for longer periods is necessary to confirm these results.
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. lipkovichia@lilly.com
authors.forename: Ilya
authors.initials: I
authors.lastname: Lipkovich
authors.forename: Jennie G
authors.initials: JG
authors.lastname: Jacobson
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Hardy
authors.forename: Vicki Poole
authors.initials: VP
authors.lastname: Hoffmann
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000453:epidemiology*; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine
references.citation: Am J Psychiatry. 2005 May;162(5):954-62
references.pmid: 15863798
references.citation: Schizophr Res. 2008 Jul;102(1-3):230-40
references.pmid: 18423985
references.citation: Schizophr Res. 2003 Jan 1;59(1):19-27
references.pmid: 12413638
references.citation: J Clin Psychiatry. 1999 Jun;60(6):358-63
references.pmid: 10401912
references.citation: Br J Psychiatry Suppl. 2004 Apr;47:S76-9
references.pmid: 15056598
references.citation: MMWR Morb Mortal Wkly Rep. 2006 Sep 15;55(36):985-8
references.pmid: 16971886
references.citation: J Clin Psychiatry. 2004 May;65(5):715-20
references.pmid: 15163261
references.citation: J Clin Psychiatry. 2001 Apr;62(4):231-8
references.pmid: 11379836
references.citation: Am J Psychiatry. 1997 Apr;154(4):457-65
references.pmid: 9090331
references.citation: J Psychopharmacol. 2005 Nov;19(6 Suppl):110-7
references.pmid: 16280344
references.citation: J Clin Psychiatry. 2005 Dec;66(12):1576-9
references.pmid: 16401160
references.citation: J Clin Psychopharmacol. 1997 Oct;17(5):407-18
references.pmid: 9315992
references.citation: Schizophr Bull. 2008 Nov;34(6):1163-71
references.pmid: 18156640
references.citation: N Engl J Med. 2005 Sep 22;353(12):1209-23
references.pmid: 16172203
references.citation: J Clin Psychopharmacol. 2006 Jun;26(3):316-20
references.pmid: 16702898
references.citation: BMC Psychiatry. 2005 Jan 13;5:3
references.pmid: 15649317
references.citation: J Clin Psychopharmacol. 2005 Jun;25(3):255-8
references.pmid: 15876905
references.citation: J Clin Psychiatry. 2005 Feb;66(2):205-12
references.pmid: 15705006
references.citation: J Nerv Ment Dis. 2005 Oct;193(10):641-6
references.pmid: 16208158
references.citation: Diabetes Care. 2004 Dec;27(12):2806-12
references.pmid: 15562189
references.citation: Ann Clin Psychiatry. 2006 Jul-Sep;18(3):163-7
references.pmid: 16923654
references.citation: Psychiatr Serv. 2003 Aug;54(8):1155-7
references.pmid: 12883145
references.citation: J Clin Psychiatry. 2001 Feb;62(2):92-100
references.pmid: 11247108
references.citation: J Nerv Ment Dis. 2004 Jun;192(6):421-7
references.pmid: 15167405
references.citation: Int Clin Psychopharmacol. 2005 Jul;20(4):199-205
references.pmid: 15933480
references.citation: J Clin Psychiatry. 2005 Feb;66(2):183-94; quiz 147, 273-4
references.pmid: 15705003